Skip to main content

Table 7 Frequencies of protein expression levels between primary and metastatic tumors

From: Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors

Protein Primary tumors Metastatic tumors Sign test, P value
  0 1 2 0 1 2  
pHER1 25 -- 5 11 -- 19 0.0003
pHER2 17 5 7 14 10 6 0.6072
pHER3 23 -- 5 16 -- 13 0.0034
Nuclear pHER3 27 -- 1 15 -- 14 0.0002
HER4 -- 13 17 -- 19 10 0.1435
Cytoplasmic pErk 10 4 15 6 12 12 1.0000
Nuclear pErk 10 3 16 6 6 18 0.4545
Cytoplasmic pAkt 3 19 8 10 5 14 0.8036
Nuclear pAkt 16 8 8 10 7 12 0.0768
  1. Category 0 = number of negative cases, category 1 = number of weak-expressing (pHER2), low-expressing (HER4) or moderate-expressing (pErk and pAkt) cases, and category 2 = number of positive (pHER1 and pHER3) or strong-expressing (pHER2, pErk and pAkt) cases. Expression of pHER1, pHER3 and nuclear pHER3 was analyzed as negative or positive, hence '--' in category 1. HER4 expression was evaluated as either low or high, hence '--' in category 0. The Sign test was used to examine for significant differences in protein expression levels between primary and metastatic tumors. Bold data represent significant values.